Skip to main content

Table 1 Study characteristics of oxidative stress (OS) markers of included studies

From: The diagnostic potential of oxidative stress biomarkers for preeclampsia: systematic review and meta-analysis

Name of oxidative stress (OS) markers Author/Reference Study design Sample Optimal cut-off Control type n (Control) PE type n (PE) GA at sampling Exclusion criteria
Ischemia-modified albumin (IMA) Ustun et al. [13] Case–control Serum  > 0.31 ABSU or ng/ml Normotensive, non-smoker 18 EOPE and LOPE are mixed 36 32–38 weeks Multiple pregnancy, chronic hypertension, renal disease, diabetes mellitus, other pre-existing disorders, the early history of preeclampsia, HELLP syndrome, immunosuppression, or a history of using illicit drugs
Vyakaranam et al. [14] Case–control Serum  > 38.33 ng/mL Normotensive 19 EOPE and LOPE are mixed 19  ≥ 32 weeks History of pregnancy complications, twin pregnancy, previous pregnancy with hypertensive disorders, pre-existing chronic conditions including diabetes mellitus, chronic hypertension, ischemic heart disease, peripheral vascular diseases
Bambrana et al. [6] Case–control Serum NA Normotensive, non-smoker 57 NA 57 30–39 weeks before delivery and after delivery within 48 h Pre-existing renal disease, thyroid disorders, chronic hypertensive disorder, gestational diabetes mellitus, epilepsy, hypertensive encephalopathy, heart disease, multiple pregnancies, fetal anatomical anomalies
Malondialdehyde (MDA) Rani et al. [22] Case–control Placental tissue 6.5 nmol/g Normotensive 30 EOPE and LOPE are mixed 30 Within 20 min of delivery Chorioamnionitis, chronic hypertension, renal disease, cardiovascular disease, active asthma, thyroid disorders, and a history of seizures
Bambrana et al. [6] Case–control Serum NA Normotensive, non-smoker 57 NA 57 30–39 weeks before delivery and after delivery within 48 h Pre-existing renal disease, thyroid disorders, chronic hypertensive disorder, gestational diabetes mellitus, epilepsy, hypertensive encephalopathy, heart disease, numerous pregnancies, fetal anatomical anomalies
Shaker et al. [23] Case–control Placental tissue 0.14 nmol/mg Normotensive 25 EOPE and LOPE are mixed 25 Immediately after delivery Pre-existing hypertension before
20 weeks gestation and women with pregnancy complications including diabetes mellitus, peripheral vascular disease, chronic renal disease, multifetal gestation, or major fetal anomalies
Uric acid (UA) Nikolic et al. [3] Case–control Serum  > 242 μmol/L Normotensive 60 EOPE and LOPE are mixed 32  ≥ 24 weeks Multifetal gestation, abnormal fetal morphology, pre-existing diseases, and gestational age prior to 24 weeks
Bambrana et al. [6] Case–control Serum NA Normotensive, non-smoker 57 NA 57 30–39 weeks before delivery and after delivery within 48 h Pre-existing renal disease, thyroid disorders, chronic hypertensive disorder, gestational diabetes, epilepsy, hypertensive encephalopathy, heart disease, numerous pregnancies, fetal anatomical anomalies
Vyakaranam et al. [15] Case–control Serum  > 4.9 mg/dL Normotensive 31 EOPE and LOPE are mixed 30  > 32 weeks Repeated abortions, previous pregnancy complications, twin pregnancy, pre-existing medical disorders: diabetes mellitus, chronic hypertension, renal diseases, cardiovascular diseases, thyroid disorders, and liver disease
  1. PE preeclampsia; EOPE early-onset preeclampsia; LOPE late-onset preeclampsia; TP true positive; FP false positive; TN true negative; FN false negative; GA gestational age; HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) syndrome; IUGR intrauterine growth retardation; GH gestational hypertension; PTB pre-term birth